178 related articles for article (PubMed ID: 33247672)
1. Effects of Quinacrine on Expression of Hippo signaling Pathway Components (LATS1, LATS2, and YAP) in Human Breast Cancer Stem Cells.
Darbankhales S; Mirfakhraie R; Ghahremani H; Asadolahi M; Saket-Kisomi K; Safakish L; Darbeheshti S; Ganjkhanlou Z; Salami S; Sirati-Sabet M
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3171-3176. PubMed ID: 33247672
[TBL] [Abstract][Full Text] [Related]
2. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
[TBL] [Abstract][Full Text] [Related]
3. An evolutionarily conserved negative feedback mechanism in the Hippo pathway reflects functional difference between LATS1 and LATS2.
Park GS; Oh H; Kim M; Kim T; Johnson RL; Irvine KD; Lim DS
Oncotarget; 2016 Apr; 7(17):24063-75. PubMed ID: 27006470
[TBL] [Abstract][Full Text] [Related]
4. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
5. miR-135b, upregulated in breast cancer, promotes cell growth and disrupts the cell cycle by regulating LATS2.
Hua K; Jin J; Zhao J; Song J; Song H; Li D; Maskey N; Zhao B; Wu C; Xu H; Fang L
Int J Oncol; 2016 May; 48(5):1997-2006. PubMed ID: 26934863
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
7.
Li L; Dong L; Wang Y; Zhang X; Yan J
Biomed Res Int; 2018; 2018():4387932. PubMed ID: 30671453
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of microRNA-224-3p Hampers Retinoblastoma Progression via Activation of the Hippo-YAP Signaling Pathway by Increasing LATS2.
Song L; Huang Y; Zhang X; Han S; Hou M; Li H
Invest Ophthalmol Vis Sci; 2020 Mar; 61(3):32. PubMed ID: 32186675
[TBL] [Abstract][Full Text] [Related]
9. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
10. Deubiquitylase USP9X suppresses tumorigenesis by stabilizing large tumor suppressor kinase 2 (LATS2) in the Hippo pathway.
Zhu C; Ji X; Zhang H; Zhou Q; Cao X; Tang M; Si Y; Yan H; Li L; Liang T; Feng XH; Zhao B
J Biol Chem; 2018 Jan; 293(4):1178-1191. PubMed ID: 29183995
[TBL] [Abstract][Full Text] [Related]
11. Src Inhibits the Hippo Tumor Suppressor Pathway through Tyrosine Phosphorylation of Lats1.
Si Y; Ji X; Cao X; Dai X; Xu L; Zhao H; Guo X; Yan H; Zhang H; Zhu C; Zhou Q; Tang M; Xia Z; Li L; Cong YS; Ye S; Liang T; Feng XH; Zhao B
Cancer Res; 2017 Sep; 77(18):4868-4880. PubMed ID: 28754671
[TBL] [Abstract][Full Text] [Related]
12. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway.
Li SY; Wang H; Mai HF; Li GF; Chen SJ; Li GS; Liang BC
Cancer Gene Ther; 2019 Nov; 26(11-12):374-387. PubMed ID: 30546116
[TBL] [Abstract][Full Text] [Related]
13. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells.
Heidary Arash E; Shiban A; Song S; Attisano L
EMBO Rep; 2017 Mar; 18(3):420-436. PubMed ID: 28183853
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of Lats1 and Lats2 highlights the role of hippo pathway effector YAP in larynx and vocal fold epithelium morphogenesis.
Mohad V; Lungova V; Verheyden J; Thibeault SL
Dev Biol; 2021 May; 473():33-49. PubMed ID: 33515576
[TBL] [Abstract][Full Text] [Related]
15. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway.
Meng Z; Moroishi T; Mottier-Pavie V; Plouffe SW; Hansen CG; Hong AW; Park HW; Mo JS; Lu W; Lu S; Flores F; Yu FX; Halder G; Guan KL
Nat Commun; 2015 Oct; 6():8357. PubMed ID: 26437443
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
17. CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status.
Feng X; Zhang M; Wang B; Zhou C; Mu Y; Li J; Liu X; Wang Y; Song Z; Liu P
J Exp Clin Cancer Res; 2019 Aug; 38(1):361. PubMed ID: 31419991
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of RASSF6 promotes breast cancer growth and chemoresistance through regulation of Hippo signaling.
He Z; Zhao TT; Jin F; Li JG; Xu YY; Dong HT; Liu Q; Xing P; Zhu GL; Xu H; Miao ZF
Biochem Biophys Res Commun; 2018 Sep; 503(4):2340-2347. PubMed ID: 29964010
[TBL] [Abstract][Full Text] [Related]
19. Hippo pathway in mammary gland development and breast cancer.
Shi P; Feng J; Chen C
Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):53-9. PubMed ID: 25467757
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
